This is a preview of subscription content, log in via an institution to check access.
Notes
¥110 = $US1 (average of 2017)
Reference
Hoshi SL, et al. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Vaccine : 29 May 2019. Available from: URL: http://doi.org/10.1016/j.vaccine.2019.05.006
Rights and permissions
About this article
Cite this article
Varicella zoster vaccines in Japan: assessing value for money. PharmacoEcon Outcomes News 830, 34 (2019). https://doi.org/10.1007/s40274-019-5985-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5985-4